Smaller, cheaper wastewater plant from ITT
A dual-stage membrane bioreactor (MBR) for advanced treatment of industrial wastewater takes up less space and has lower operating costs than conventional activated sludge processing systems.
Archives for January 10, 2005
Roche extends NanoCrystal license
Ireland's Elan has altered its licensing agreement with Roche to give the Swiss firm expanded access to a technology designed to improve the performance of drugs.
Agilent Technologies announces microarray platform expansion
A hive of activity at Agilent Technologies has trnsformed the company into a significant player in the competitive microarray platform market with the expansion of its array-based genomics, disease research and drug R&D applications.
Contact lenses deliver drugs to eye
Researchers in Singapore have developed a novel way of delivering drugs into the eye - load them into contact lenses.
Will FDA's axe fall on COX-2s?
A new report suggests that recent safety concerns over certain blockbuster drugs, notably Merck's Vioxx (rofecoxib) and Pfizer's Celebrex (celecoxib), has placed the COX-2 inhibitor drug class under intense scrutiny and places the US Food and Drug...
Paradigm acquires Amedis to accelerate drug discovery
Paradigm Therapeutics has announced it has completed the acquisition of Amedis Pharmaceuticals with the aim of identifying highly druggable targets and novel compounds for conditions in the areas of CNS, pain, endocrinology and metabolism.
Vivascience IPO shelved once again
Germany's Sartorius has decided to call off the initial public offering of Vivascience, which makes products for the analysis and purification of proteins.
Albumin delivery improves breast cancer therapy
A widely used drug to treat breast cancer has been significantly improved by the use of a new technology that binds it to albumin, a common constituent of human blood.
Antisoma acquires cancer company Aptamera
UK cancer specialist Antisoma has entered into an agreement to acquire Aptamera in an £11.5 million (€16.5 million) deal, which aims to pioneer a new drug therapy in the emerging new area of anticancer aptamers.